AUPH - Aurinia Pharmaceuticals Inc.
| Previous Close | 5.49 |
| Open | 5.49 |
| Bid | 5.35 x 1400 |
| Ask | 5.58 x 800 |
| Day's Range | 5.28 - 5.57 |
| 52 Week Range | 4.41 - 6.69 |
| Volume | 580,064 |
| Avg. Volume | 532,293 |
| Market Cap | 471.002M |
| Beta (3Y Monthly) | 1.83 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.63 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.92 |
- Business Wire•10 days ago
Aurinia to Participate in November Investor Conferences
Aurinia Pharmaceuticals Inc., today announced its Chairman and CEO, Richard Glickman, will participate in two upcoming investor conferences.
- Zacks•11 days ago
Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue Estimates
Aurinia (AUPH) delivered earnings and revenue surprises of -23.53% and 476.92%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•11 days ago
Aurinia: 3Q Earnings Snapshot
The Victoria, British Columbia-based company said it had a loss of 21 cents per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
- Business Wire•11 days ago
Aurinia Reports Third Quarter Financial Results, Clinical Highlights and Corporate Development
VICTORIA, British Columbia-- -- AURORA Phase III Trial in lupus nephritis completes enrollment ahead of schedule Phase II data for the treatment of dry eye expected in January 2019 Phase II FSGS Trial ongoing Richard M. Glickman announces his intention to retire as CEO next year, upon identification and appointment of an appropriate successor Aurinia Pharmaceuticals Inc. has released its financial ...
- Business Wire•25 days ago
Aurinia Pharmaceuticals to Release Third Quarter Financial Results and General Business Updates on November 8, 2018
Conference Call and webcast to follow
- GlobeNewswire•last month
New Research: Key Drivers of Growth for Haverty Furniture Companies, BLACKLINE INC, MagnaChip Semiconductor, Kinross Gold, Aurinia Pharmaceuticals, and NEXEO SOLUTIONS — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Oct. 16, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Motley Fool•2 months ago
Here's What Pushed Aurinia Pharmaceuticals Inc. Up 16.8% in September
Steady progress for the company's experimental lupus treatment took an important step forward
- Zacks•2 months ago
Aurinia Pharmaceuticals (AUPH) in Focus: Stock Moves 6.7% Higher
Aurinia Pharmaceuticals (AUPH) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
- Benzinga•2 months ago
The Daily Biotech Pulse: Verastem's Chinese Duvelisib Licensing Deal, Aldeyra's Positive Dry Eye Disease Drug Trial
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Sept. 25) Abbott Laboratories (NYSE: ABT ) Amarin Corporation ...
- Business Wire•2 months ago
Aurinia Completes Enrollment of AURORA, its Phase 3 Clinical Trial for the Treatment of Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced that it has completed enrollment for the AURORA Phase 3 trial ahead of schedule. The target enrollment of 324 patients was surpassed due to high patient demand with 358 lupus nephritis (LN) patients randomized in sites across 27 countries. “We are elated by the significant interest this trial has garnered around the globe, which reinforces the need for new treatment options for patients living with lupus nephritis,” said Richard M. Glickman, Aurinia’s Chairman and Chief Executive Officer.
- Business Wire•2 months ago
Aurinia to Participate in Upcoming Investor Conferences
Aurinia Pharmaceuticals Inc., today announced its Chairman and CEO, Richard Glickman, will present a company overview at two upcoming investor conferences.
- Business Wire•3 months ago
Aurinia Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018
Aurinia Pharmaceuticals Inc., (AUPH)(AUP.TO) today announced it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 4-6, 2018 at the St. Regis New York Hotel in New York City. Celia Economides, Vice President of Corporate and Public Affairs, will provide an overview of the Company's business on Thursday, September 6 at 10:50am ET. If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.rodmanevents.com) to register for the conference.
- Zacks•3 months ago
Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates
Aurinia (AUPH) delivered earnings and revenue surprises of -18.75% and 447.17%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•3 months ago
Aurinia: 2Q Earnings Snapshot
The Victoria, British Columbia-based company said it had a loss of 19 cents per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
- Business Wire•3 months ago
Aurinia Reports Second Quarter Financial Results and Operational Highlights
AURORA Phase III Trial in lupus nephritis anticipated to complete enrollment ahead of schedule
- Simply Wall St.•3 months ago
Aurinia Pharmaceuticals Inc’s (TSE:AUP) Shift From Loss To Profit
Aurinia Pharmaceuticals Inc’s (TSE:AUP): Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada,Read More...
- Business Wire•4 months ago
Aurinia Pharmaceuticals to Release Second Quarter 2018 Financial Results on August 9, 2018
Conference Call and webcast to follow
- Investopedia•4 months ago
5 Favorite Biotech Bets
Given their dependence on the success or failure of their drug candidates, biotechnology stocks are generally high-risk propositions. Over the past couple of decades our most profitable sector has been biotech stocks. Of course, the key to almost any stock move is news.
- Motley Fool•4 months ago
Here's Why Aurinia Pharmaceuticals Inc. Gained 32.2% in the First Half of 2018
An additional indication for the company's lead candidate has been a big source of encouragement.
- InvestorPlace•4 months ago
Aurinia Pharmaceuticals Has Lots of Upside Potential
Since last year, Aurinia Pharmaceuticals (NASDAQ:AUPH) has moved very little on the stock market. News of the launch of a mid-stage study, along with a quarterly earnings report before that, failed to ignite or hurt AUPH stock by much. On July 11, Aurinia launched a mid-stage Phase 2 clinical study that evaluates its drug, Voclosporin, for treating dry eye syndrome (or DES).
- Benzinga•4 months ago
Benzinga's Daily Biotech Pulse: AbbVie Files sNDA For Leukemia Drug, AcelRx Offering, Aurinia Starts Mid-Stage Trial
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 11) AC Immune SA (NASDAQ: ACIU ) Arbutus Biopharma Corp (NASDAQ: ...
- Business Wire•4 months ago
Aurinia Initiates Phase 2 Clinical Trial for Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX: AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the initiation of its Phase 2 trial evaluating voclosporin ophthalmic solution (VOS) for the treatment of dry eye syndrome (DES). VOS, which is a proprietary nanomicellar formulation, enables high concentrations of voclosporin to be incorporated into a clear aqueous, preservative-free solution for local delivery to the ocular surface. This patented formulation has the potential to result in improved efficacy, dosing frequency, and tolerability versus the current treatments for DES.
- ACCESSWIRE•5 months ago
Free Technical Reports on Array BioPharma and Three Additional Biotech Equities
Under observation are these four equities: Ardelyx Inc. (NASDAQ: ARDX), Array BioPharma Inc. (NASDAQ: ARRY), Audentes Therapeutics Inc. (NASDAQ: BOLD), and Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH). All you have to do is sign up today for this free limited time offer by clicking the link below.
- Business Wire•5 months ago
Aurinia Initiates Clinical Trials Broadening the Development of Voclosporin
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the enrollment of the first patients into the AURORA 2 extension study in lupus nephritis and the initiation of its Phase II trial in focal segmental glomerulosclerosis (FSGS). The first patients have rolled over into the AURORA 2 extension study from the AURORA Phase III clinical trial for lupus nephritis.
